Research peptides, evidence, methods and laboratory practice
We read the papers and report what follows from them, along with what does not.
Evidence reviews & mechanisms
The Science
Research 15 November 2026
TRIUMPH-2: retatrutide in type 2 diabetes, and why the numbers are smaller
The second pivotal trial moved the compound into a harder population: adults with obesity who also have type 2 diabetes. The weight figures are lower than in TRIUMPH-1, and that gap is not a disappointment. It is the single most consistent finding in the entire incretin class.
3 min read · 4 sources
Research 13 November 2026
The peptide that came out of a lizard: how exendin-4 started the incretin class
Every weekly GLP-1 injection on the market descends from a molecule found in the saliva of a venomous desert lizard in 1992. The story is usually told as a curiosity. It is better told as a case study in how a research observation becomes a drug, and how long that takes.
3 min read · 3 sources
Research 7 November 2026
TRIUMPH-1: what the first phase 3 retatrutide trial actually measured
The phase 2 record for retatrutide was 338 people over 48 weeks. TRIUMPH-1 is 2,339 people over 80 weeks, peer-reviewed in the New England Journal of Medicine. This is the trial that moves the compound from a promising signal to a registration dossier, and the numbers deserve a closer read than the headline.
4 min read · 4 sources
Research 5 November 2026
CJC-1295 vs ipamorelin: two receptors compared side by side
These two are almost always discussed as a pair, and unusually the pairing has a real basis, they act through different receptors, so combining them is a coherent design rather than doubling up. But one of them has a naming problem serious enough that the trial data people quote may not describe the material they are holding.
3 min read · 3 sources
Reconstitution, storage & methods
The Lab
Basics 11 November 2026
Why a peptide that lasts two minutes in the blood can be dosed once a week
Native GLP-1 is destroyed within minutes. Semaglutide, tirzepatide and retatrutide last days. The difference is a fatty acid stapled to the peptide, and the trick it plays on the body's most abundant blood protein.
3 min read · 3 sources
Basics 9 November 2026
GIP, GLP-1 and glucagon: the three receptors, explained without a biochemistry degree
Every description of retatrutide says it hits three receptors. Almost none explains what the three do, why the third one was considered a mistake for twenty years, or why engaging all of them at once is harder than it sounds.
3 min read · 3 sources
Guide 30 October 2026
What the paperwork can prove, and where it stops
A certificate, a sequence, a purity figure and a body of published literature are four different kinds of evidence about a research compound. Each answers a real question and none answers the one buyers most want answered. This is where the boundary actually falls.
3 min read · 2 sources
Guide 28 October 2026
Aliquot first: the five minutes that protect a stock
Splitting a solution into single-use portions is the most consistently recommended and most consistently skipped step in peptide handling. The advice is not fussiness, it exists because each freeze, thaw cycle does damage by a specific mechanism, and the damage does not undo itself.
3 min read · 2 sources
How these pieces are written
Every figure is cited
Every number comes from a published study and carries a DOI link. Figures are reused only from openly licensed papers, always with a credit line.
Including what is not known
We state where the evidence stops, how many studies ran in humans versus animals, and what a given paper does not settle.
Not medical advice
We describe these materials as reagents for in-vitro laboratory research. We do not suggest any use in humans or animals.